每日经济新闻 展望后市，中信建投证券表示：2026年全球降息周期进入下半场，宏观流动性呈"内外宽松共 振"与"从超常到常态"两大核心特征。汇率端美元承压，人民币升值支撑A股走强。股债再配置层面， 长期低利率重塑股债配置逻辑，中期"股债跷跷板"效应进一步支撑A股走势。除此之外，居民"存款搬 家"再配置的需求或将成为市场的最大边际增量。政策方面，后地产时代资本市场地位升级，成为经济 发展与资源配置的核心枢纽，市场资金生态持续优化，为资本市场高质量发展奠定基础。 A500ETF基金（512050）助力投资者一键布局A股核心资产，把握A股估值抬升红利。该ETF具备 费率低（综合费率仅0.2%）、流动性好（近一月日均成交额超50亿元）、规模大（规模超400亿元）等 核心优势。其跟踪中证A500指数，采取行业均衡配置与龙头优选双策略，中证全部35个细分行业全覆 盖，融合价值与成长属性，相比沪深300，超配AI产业链、医药生物、电力设备新能源等新质生产力行 业，具备天然的哑铃投资属性。 投资者可关注相关产品：A500ETF基金（512050）（场外联接：A类：022430；C类：022431；Y 类：022979）、A50 ...

证券时报·数据宝统计，截至今日上午10:29，上证综指4107.01点，收于半年线之上，涨跌幅-0.46%，A 股总成交额为14299.56亿元。到目前为止，今日有98只A股价格突破了半年线，其中乖离率较大的个股 有新威凌、神宇股份、文科股份等，乖离率分别为7.90%、7.78%、7.77%；川环科技、铁科轨道、ST华 扬等个股乖离率较小，刚刚站上半年线。 （文章来源：证券时报网） 1月15日突破半年线个股乖离率排名 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 920634 | 新威凌 | 12.46 | 10.41 | 27.77 | 29.97 | 7.90 | | 300563 | 神宇股 份 | 8.73 | 12.74 | 38.95 | 41.98 | 7.78 | | 002775 | 文科股 份 | 10.09 | 3.41 | 4.45 | 4.80 | 7.77 | | ...

通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 证券之星消息，截至2026年1月13日收盘，通策医疗(600763)报收于42.48元，上涨0.33%，换手率 3.4%，成交量15.21万手，成交额6.53亿元。 1月13日的资金流向数据方面，主力资金净流出1238.96万元，占总成交额1.9%，游资资金净流入 1690.08万元，占总成交额2.59%，散户资金净流出451.12万元，占总成交额0.69%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

证券日报网讯 1月12日，通策医疗在互动平台回答投资者提问时表示，截至2026年1月10日公司股东总 数为9万多户。为确保所有投资者能公平地获取信息，相关股东人数信息后续请以公司正式披露的定期 报告为准。 （文章来源：证券日报） ...

证券之星消息，截至2026年1月12日收盘，通策医疗(600763)报收于42.34元，上涨1.61%，换手率 2.38%，成交量10.63万手，成交额4.48亿元。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同 ...

来源：市场资讯 有投资者在互动平台向通策医疗提问："请问截止2026年1月10日公司的股东数是多少？" 针对上述提问，通策医疗回应称："您好，截至2026年1月10日公司股东总数为9万多。为确保所有投资 者能公平地获取信息，相关股东人数信息后续请以公司正式披露的定期报告为准，感谢您的关注。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

证券之星消息，截至2026年1月7日收盘，通策医疗(600763)报收于41.02元，下跌0.65%，换手率 1.34%，成交量5.99万手，成交额2.46亿元。 1月7日的资金流向数据方面，主力资金净流出2848.85万元，占总成交额11.56%，游资资金净流入 914.14万元，占总成交额3.71%，散户资金净流入1934.71万元，占总成交额7.85%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88 ...

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown a slight increase in stock price and has reported positive financial performance in its recent quarterly results [1][2] - As of January 6, 2026, Tongce Medical's stock closed at 41.29 yuan, with a trading volume of 79,900 hands and a total transaction amount of 329 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 9.82 million yuan, while retail investors saw a net inflow of 10.79 million yuan, indicating a mixed sentiment among different investor groups [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The company's third-quarter results showed a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, and a net profit of 192 million yuan, up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while maintaining a gross profit margin of 41.69% [2]

该股主要指标及行业内排名如下： 证券之星消息，截至2026年1月5日收盘，通策医疗(600763)报收于41.14元，上涨2.31%，换手率 1.75%，成交量7.81万手，成交额3.19亿元。 1月5日的资金流向数据方面，主力资金净流出3346.42万元，占总成交额10.49%，游资资金净流入 1248.28万元，占总成交额3.91%，散户资金净流入2098.15万元，占总成交额6.58%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-05 | 41.14 | 2.31% | -3346.42万 | -10.49% | 1248.28万 | 3.91% | 2098.15万 | - 6.58% | | 2025-12-31 | 40.21 | -0.30% | -630.53万 | -3.86% | 285.32万 | 1.75% | 345.21万 | 2.11% | | ...